Orthopedics This Week | February 16, 2016 | Page 23

ORTHOPEDICS THIS WEEK
VOLUME 12, ISSUE 6 | FEBRUARY 16, 2016

“AccelSPINE is a leader in our industry,
and it has a proven track record of producing exceptional medical products.
Acquiring AccelSPINE not only helps
advance our global growth strategy,
but it also helps us meet the needs of
our growing customer base,” said CTL
Medical Chief Business Development
Officer Andy Choi.
The CTL Medical Corporation plans
to retain all of AccelSPINE’s current
employees and executives, and anticipates a significant increase in its workforce by early 2017.
Chon founded CTL Medical Corporation in 2015. His vision was to create a fully integrated, industry leading, global medical device design,
development and manufacturing
company. — BY

ty test. The company uses gene-based
information to develop new diagnostics
that assess a person’s risk of disease and
therapeutic products designed to effectively prevent and/or treat diseases.
Two of those diseases are scoliosis and
degenerative disc disease (DDD).

LEGAL

Genetic Testing of
Spine Disease Wins
Patent Ruling

E

23

fforts to develop genetic diagnostics
for spinal diseases received a boost
as Predictive Therapeutics, a subsidiary of Predictive Technology Group,
Inc. (PRED) of
Salt Lake City,
Utah, announced
a favorable ruling from the U.S.
Patent and Trademark Office’s Patent and Appeal
Board (PTAB) for
its spine deformi-

On February 2, 2016, the company
announced that the favorable ruling
related to the spinal deformity molecular diagnostic tests and companion

Courtesy of Predictive Therapeutics

Advertisement

ryortho.com | 1-888-749-2153